

# Derivation, characterisation and analysis of an adverse outcome pathway network for human hepatotoxicity

Emma Arnesdotter<sup>a</sup>, Nicoleta Spinu<sup>b</sup>, James Firman<sup>b</sup>, David Ebbrell<sup>b</sup>, Mark TD Cronin<sup>b\*</sup>, Tamara Vanhaecke<sup>a\*</sup> Mathieu Vinken<sup>a\*#</sup>

<sup>a</sup>Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Jette, Brussels, Belgium

<sup>b</sup>School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, James Parsons Building, Byrom Street, L3 3AF Liverpool, United Kingdom

*\* these authors share equal seniorship,*

# Correspondence to Prof. Mathieu Vinken, Ph.D., Pharm.D., E.R.T., Department of Pharmaceutical and Pharmacological Sciences, Faculty of Medicine and Pharmacy, Laarbeeklaan 103, Vrije Universiteit Brussel, 1090 Brussels, Belgium; Tel.: +32 2 477 45 87; Website: [www.mathieuvinken.com](http://www.mathieuvinken.com); E-mail: [mathieu.vinken@vub.be](mailto:mathieu.vinken@vub.be).

## ORCID and email address to authors

Emma Arnesdotter 0000-0002-5891-5479, [emma.arnesdotter@vub.be](mailto:emma.arnesdotter@vub.be); Nicoleta Spinu 0000-0002-9465-3090, [n.spinu@2017.ljmu.ac.uk](mailto:n.spinu@2017.ljmu.ac.uk); James Firman 0000-0003-0319-1407, [j.w.firman@ljmu.ac.uk](mailto:j.w.firman@ljmu.ac.uk); David Ebbrell 0000-0001-5329-7539, [d.ebbrell@ljmu.ac.uk](mailto:d.ebbrell@ljmu.ac.uk); Mark TD Cronin 0000-0002-6207-4158, [M.T.Cronin@ljmu.ac.uk](mailto:M.T.Cronin@ljmu.ac.uk); Tamara Vanhaecke 0000-0002-6685-7299, [tamara.vanhaecke@vub.be](mailto:tamara.vanhaecke@vub.be); Mathieu Vinken 0000-0001-5115-8893, [mathieu.vinken@vub.be](mailto:mathieu.vinken@vub.be)

## Abstract

Adverse outcome pathways (AOPs) and their networks are important tools for the development of mechanistically based non-animal testing approaches, such as *in vitro* and/or *in silico* assays, to assess toxicity induced by chemicals. In the present study, an AOP network connecting 14 linear AOPs related to human hepatotoxicity, currently available in the AOP-Wiki, was derived according to established

criteria. The derived AOP network was characterised and analysed with regard to its structure and topological features. In-depth analysis of the AOP network showed that cell injury/death, oxidative stress, mitochondrial dysfunction and accumulation of fatty acids are the most highly connected and central key events. Consequently, these key events may be considered as the rational and mechanistically anchored basis for selecting, developing and/optimising *in vitro* and/or *in silico* assays to predict hepatotoxicity induced by chemicals in view of animal-free hazard identification.

## Key words

Adverse outcome pathway; predictive toxicology; network derivation; hepatotoxicity.

## Abbreviations

ACC-1 Acetyl-CoA carboxylase; AO Adverse outcome; AOP Adverse outcome pathway; AKT2 RAC- $\beta$  serine/threonine-protein kinase; BSEP Bile salt export pump; CAR Constitutive androstane receptor; CD36 Cluster of differentiation 36; FA Fatty acid; FXR Farnesoid X receptor; GR Glucocorticoid Receptor; HSC Hepatic stellate cells; KE Key event; KER Key event relationship; MIE Molecular initiating event; LXR Liver X receptor; OECD Organisation for Economic Cooperation and Development; OST $\alpha/\beta$  Organic solute transporter  $\alpha/\beta$ ; PXR Pregnane X receptor; ROS Reactive oxygen species; SCD-1 Stearoyl-CoA desaturase-1; TG Triglyceride

## 1. Introduction

The adverse outcome pathway (AOP) is a conceptual framework used to aggregate and organise biological knowledge, which can be employed to translate mechanistic data into outcomes relevant to chemical safety assessment (Ankley et al. 2010). AOPs are modular and consist of a molecular initiating event (MIE), one or more key event(s) (KEs) and an adverse outcome (AO), which represent responses at different levels of biological organisation. Key event relationships (KERs) specify the causal linkages between each KE across multiple biological levels of organisation (Vinken 2013; Vinken et al. 2017). In 2012, the Organisation for Economic Cooperation and Development (OECD) launched

a programme for the development of AOPs, and later developed a guidance document to standardise the construction and assessment of AOPs (OECD 2017). The OECD, along with a number of other stakeholders, also introduced the AOP Knowledgebase (<https://aopkb.oecd.org/>), which serves as the primary repository for AOPs. The AOP-Wiki (<https://aopwiki.org/>) represents one of the five modules of the AOP Knowledgebase. At present, the AOP-Wiki contains 320 AOPs, more than 1390 KEs and as many as 1860 KERs.

Although AOPs are assumed to be chemical agnostic, they can support the use of a mode (and/or mechanism) of action basis for understanding adverse effects of chemicals and other stressors. In recent years, emphasis has been placed on AOPs as a conceptual support in the construction of mechanistically based non-animal testing approaches consisting of a combination of *in vitro* and *in silico* methods (Burden et al. 2015; Kleinstreuer et al. 2016; Sakuratani et al. 2018; Vinken 2018; Parish et al. 2020). The general principle of the use of these approaches is that a limited set of (measurable) KEs can sufficiently describe or predict a toxicological response (Worth and Patlewicz, 2016). If AOPs are to be useful for safety assessment purposes, rather than merely serving hazard identification or characterisation, it is crucial that the KERs in an AOPs reflect quantitative elements of the toxicity pathway (Carusi et al. 2018; Sewell et al. 2018). However, linear AOPs may be of limited use for the purpose of safety assessment, as biological processes are in most cases complex (Sewell et al. 2018). Indeed, interaction and crosstalk between biological pathways are acknowledged to be the norm rather than the exception. So-called AOP networks provide the actual tools for real-life applications of AOPs, as they more realistically represent interactions occurring in a systems biology context (Villeneuve et al. 2014). An AOP network is defined as an assembly of two or more linear AOPs that share one or more KEs, including the MIE and AO. In an AOP network, KEs represent nodes, while KERs are reflected as directed edges that link those nodes together (OECD 2018). AOP networks open the possibility of linking toxicological pathways, thus highlighting areas where one assay could predict multiple outcomes or converge multiple MIEs (Knapen et al. 2018). Network science provides the means to quantitatively analyse AOP networks and identify such KEs of interest (Sturla et al. 2014;

Hartung et al. 2017; Villeneuve et al. 2018). In this respect, an AOP network for neurotoxicity was previously introduced (Spinu et al. 2019) based on established guidelines regarding AOP network derivation, characterisation and analysis (Knapen et al. 2018; Villeneuve et al. 2018). In the present study, a similar exercise was undertaken focused on hepatotoxicity with the aim to identify relevant KEs that could form the basis for setting up a battery of *in vitro* and/or *in silico* assays for predictive toxicity screening of chemicals.

## 2. Materials and Methods

### 2.1. Data set

The OECD AOP-Wiki 2.0 was manually searched to identify linear AOPs related to hepatotoxicity and to derive the AOP network according to previously published criteria (Spinu et al. 2019). For each individual AOP, the following information was extracted: KE title, KE type (*i.e.* MIE, KE, AO), KER (*i.e.* linkage between upstream and downstream KEs), adjacency of the relationship between a pair of KEs, qualitative weight of evidence (WoE) (*i.e.* low, moderate, high), AOP development stage as reported by the AOP developer, and progress through the OECD review and endorsement processes. The information regarding individual AOPs was extracted 1 September 2020. All data collected are available as supplementary material (Appendix 1).

### 2.2. AOP network derivation

The process of deriving the hepatotoxicity AOP network was performed following four steps as described elsewhere (Spinu et al. 2019).

#### Step 1 - Definition of purpose

The present study aimed to identify the most common and the most highly connected KEs in a hepatotoxicity AOP network that could be measured in *in vitro* assays to assist in the prediction of adverse effects of chemicals on the liver. Accordingly, the scope of the study included AOPs developed for hepatotoxicity and published in the AOP-Wiki.

## Step 2 - Definition of criteria for AOP selection

AOPs were selected based on the following criteria: the taxonomic applicability and the AOP development stage in terms of the progress of the AOP through the OECD review and endorsement processes. Taxonomy was considered the main criterion for collecting individual AOPs (*i.e.* those applicable and relevant for humans). The AOP development stage was considered, as it indicates the level of maturity of the AOPs used to derive the AOP network. The difference between adjacent KERs and non-adjacent KERs, previously termed “indirect KERs”, was taken into consideration. Additionally, the WoE for the relationships between the KEs, which relied on the assessment performed by the AOP developers, described as low, medium or high, was considered.

## Step 3 - Identification of appropriate AOPs from the AOP-Wiki and data curation

AOPs identified according to the criteria in step two were evaluated and collected manually in an Excel spreadsheet. In the cases where KEs were given different titles, while having the same meaning and/or referring to the same process, they were grouped and renamed under a common KE title. Wherever possible, abbreviations have been used. All amendments to KE titles are described in the Excel spreadsheet available as supplementary material (Appendix 1).

## Step 4 - Generation and analysis of the network

Cytoscape 3.8.0 (<https://cytoscape.org/>), which is an open source software platform, was used to model the AOP network. NetworkAnalyzer 4.4.6 App, pre-installed in the Cytoscape software, was used to analyse the derived network. The nodes (*i.e.* KEs) were manually positioned to maximise readability. Information regarding WoE, adjacency and type of KE were added to further define the visual attributes of the AOP network. KERs shared by more than one AOP are represented by a single arrow, though such multiple relationships between KEs were considered during network analysis.

### 2.3. Network analysis

The derived network was analysed using Cytoscape NetworkAnalyzer 4.4.6 App. The level of degree, betweenness centrality and eccentricity were used to characterised the network analytically due to

their ability to quantify the position of a KE in relation to its neighbour KEs in the network (Spinu et al. 2019). By analysing the network as a directed graph, the level of indegree and outdegree was used to identify points of convergence and divergence, as well as to analyse the overall connectivity of the KEs across the network. The most upstream and downstream KEs were assessed based on the analysis of the eccentricity and betweenness centrality. With the non-directed analysis of the AOP network, the eccentricity was used to identify the most central KEs in the AOP network. The combined consideration of all parameters was used to identify the most highly connected and central KEs.

### 3. Results and discussion

#### 3.1. Derivation of an AOP network for human hepatotoxicity

By manually searching the AOP-Wiki, 30 AOPs related to human hepatotoxicity were identified. Of those, 16 were considered suitable to be included in the network based on the defined criteria. As AOP ID 58 (NR1I3 (CAR) suppression leading to hepatic steatosis) was believed to be a more comprehensive version of AOP ID 34 (LXR activation leading to hepatic steatosis), it was decided to exclude the latter from the data set. Detailed information on the included AOPs is provided in Table 1. To aid readability, only the AOP ID and a note to indicate the MIE (*i.e.* AOP ID 58/CAR) will be used throughout the text. Differences in KE annotation (*i.e.* discrepancies between KE titles albeit the action refers to the same process) was previously identified as a challenge in the development of AOP networks (Spinu et al. 2019). In the present study, multiple KEs relating to the same process were identified, albeit being titled differently. In this respect, KE 327 (accumulation, fatty acid), KE 838 (induction, microvesicular fat) and KE 1305 (increase, cytosolic fatty acid) all refer to the accumulation of fatty acids (FAs), but they are titled differently. These inconsistencies in KE annotation were expected to have a major impact on the construction of the AOP network. For this reason, discrepancies in annotation have been reviewed and KEs addressing the same process have been grouped or renamed under common KE titles. Annotation changes are provided in the supplementary material (Appendix 1).

Non-adjacent KERs describe the relationship between KEs that are not next to one another in the sequence defined for the AOP and help to more thoroughly capture the WoE supporting an AOP while maintaining the modular structure (Villeneuve et al. 2018). Non-adjacent KERs have been reported likely to be associated with more than one biological process (Spinu et al. 2019). Hence, an AOP network containing both adjacent and non-adjacent KERs implies more connections, thereby representing a higher level of biological complexity. However, inclusion of non-adjacent KERs in the analysis of an AOP network has been suggested to inflate node degree and betweenness centrality or deflate distance-based calculations like eccentricity (Villeneuve et al. 2018). Moreover, if a KE is to be useful for the prediction of adverse effects and be fit to serve as a basis for *in vitro* and/or *in silico* assay selection and/or development, a detailed quantitative description of the relationship between KEs is required (Carusi et al. 2018). Consequently, it is called for that the AOP network relies on directly connected KEs to facilitate an accurate quantitative simulation of the AOP network. The difference between adjacent and non-adjacent KERs was considered accordingly and a total of nine non-adjacent KERs from five different AOPs, including AOP ID 38/PROTEIN ALKYLATION, AOP ID 58/CAR, AOP ID 60/PXR, AOP ID 220/CYP2E1 and AOP ID 278/IKK, were excluded. In addition, one AOP (AOP ID 62 AKT2 activation to steatosis) containing (solely) three non-adjacent KERs was omitted from the dataset. Due to the removal of the non-adjacent KERs, including AOP ID 62, there was a discrepancy of four KEs between the two AOP networks, namely, activation of RAC- $\beta$  serine/threonine-protein kinase (AKT2), chronic inflammation, increased tumour necrosis factor  $\alpha$  (TNF $\alpha$ ) and liver cancer.

A network of 14 AOPs (Table 1), all of which were found to share common KEs, was ultimately derived (Figure 1). A hepatotoxicity AOP network including all KERs (*i.e.* non-adjacent KERs and adjacent KERs) is available as supplementary material (Figure S1, Appendix 2). The derived hepatotoxicity AOP network consists of 14 linear AOPs related to various AOs, including cholestasis (1), steatosis (4), fibrosis (3), steatohepatitis (1), liver injury, described as the altered state of the liver wherein the normal homeostasis of all processes in the liver are perturbed, (3) and hepatotoxicity, defined as cell death (1). Not surprisingly, there is no adjacent relationships between any KE and the AO cancer (AOP

ID 220/CYP2E1). Therefore, albeit AOP ID 220/CYP2E1 is present in the network, its AO, defined as liver cancer, lost its connection to the network as it is connected to the upstream KEs (*i.e.* increased reactive oxygen species (ROS), cell injury/death and sustained cell proliferation) exclusively through non-adjacent KERs. For this reason, the AO liver cancer is not present in the network containing only adjacent KERs (Figure 1).

### 3.2. Characterisation and analysis of the AOP network for human hepatotoxicity

AOP networks can contribute to the knowledge regarding interactions among linear AOPs and analysis thereof can reveal unexpected or overlooked connections between toxicity pathways. The analysis was performed on the derived AOP network for hepatotoxicity involving 14 AOPs (Table 1) with a total of 82 unique KEs and their adjacent relationships (Appendix 1). No single KE was present in all 14 AOPs. The most common KE across all AOPs is cell injury/death, which is shared by six out of the 14 AOPs (*i.e.* AOP ID 36/PPAR, AOP ID 144/LYSOSOMAL UPTAKE, AOP ID 209/SREBF2, AOP ID 220/CYP2E1, AOP ID 273/MITOCHONDRIAL INHIBITION and AOP ID 278/IKK) (Figure 2a&b), thereby connecting linear AOPs leading to steatosis, fibrosis, hepatotoxicity, cancer and liver injury. In the network, cell injury/death is triggered by multiple mechanisms, including perturbation of cholesterol, altered glutathione homeostasis, protein alkylation, mitochondrial dysfunction, increased ROS, impaired proteostasis and activation of the caspase 8 pathway. Perturbation of this KE leads to tissue resident cell activation, release of pro-inflammatory mediators, sustained cell proliferation and presence of necrotic tissue.

FA accumulation, decreased  $\beta$ -oxidation and steatosis are all shared by five AOPs (Figure 2a&b). Steatosis and decreased  $\beta$ -oxidation are shared by the same five AOPs (*i.e.* AOP ID 36/PPAR, AOP ID 58/CAR, AOP ID 60/PXR, AOP ID 213/B-OXIDATION and AOP ID 318/GR). Of those, steatosis is the AO in all but one AOP (AOP ID 213/B-OXIDATION) in which the AOP is defined as steatohepatitis. In the network, steatosis is prompted by increased triglyceride (TG) formation, FA accumulation, and decreased  $\beta$ -oxidation. In AOP ID 213/B-OXIDATION, decreased  $\beta$ -oxidation is considered the MIE.



Additionally, decreased  $\beta$ -oxidation is triggered by decreased 3-hydroxyacyl-CoA dehydrogenase type-2 activity, downregulation of CPT1A, activation of glucocorticoid receptor (GR) and decreased PPAR- $\alpha$  activation. Downstream KEs include FA accumulation and steatosis. FA accumulation is present in AOP ID 36/PPAR, AOP ID 58/CAR, AOP ID 60/PXR, AOP ID 130/PHOSPHOLIPASE A and AOP ID 213/B-OXIDATION. It is not surprising that FA accumulation is a common event, since it is a hallmark of hepatic steatosis (Ipsen et al. 2018) which is the defined AO in four AOPs, and a KE in one AOP, included in the network. FA accumulation is prompted by increased *de novo* FA synthesis, increased FA influx and decreased  $\beta$ -oxidation all of which are indicative of disruption of the FA metabolism (Alves-Bezerra and Cohen 2018), as well as ballooning and vacuolisation of hepatocytes, and vacuolisation of Kupffer and bile duct cells. FA accumulation results in increased TG formation and steatosis. KEs shared by three AOPs include fibrosis, liver injury, activation of hepatic stellate cells (HSC), decreased PPAR- $\alpha$  activation, increased ROS, release of pro-inflammatory mediators and mitochondrial dysfunction. Mitochondrial dysfunction is involved in a feedback loop mechanism together with increased mitochondrial ROS (Figure S1, Appendix 2). KEs shared by two AOPs include accumulation of collagen, increased *de novo* FA synthesis, increased FA influx, increased TG formation, presence of necrotic tissue, up-regulation of cluster of differentiation 36 (CD36) and up-regulation of stearoyl-CoA desaturase-1 (SCD-1).

The MIE defined as decreased PPAR- $\alpha$  activation is the single MIE shared by multiple AOPs (*i.e.* AOP ID 58/CAR, AOP ID 36/PPAR and AOP ID 318/GR), which all are leading to steatosis. Conversely, several AOPs have multiple MIEs (*i.e.* AOP ID 36/PPAR (2), AOP ID 58/CAR (4) and AOP ID 273/MITOCHONDRIAL INHIBITION (8)). The latter AOP, ultimately leading to liver injury, stands out in terms of number of MIEs, which are all connected downstream to the KE decreased oxidative phosphorylation. However, this may be due to an unconventional or even incorrect structure of the AOP, rather than a true representation of the pathway. Furthermore, the structure of AOP ID 209/SREBF2 deviates, as this particular AOP is lacking a defined MIE. Both AOP ID

273/MITOCHONDRIAL INHIBITION and AOP ID 209/SREBF2 are currently stated as to be under development in the AOP-Wiki.

By using the edge count, it was found that the most hyperlinked KEs in the AOP network are accumulation of FA, cell injury/death, mitochondrial dysfunction, decreased  $\beta$ -oxidation and the AO steatosis, with a level of degree of 17, 12, 11, 9 and 9, respectively. The majority of the least connected KEs are defined as MIEs. Exceptions include the AO steatohepatitis for which only one AOP exist, and the KEs upregulation of acetyl-CoA carboxylase (ACC-1), decreased ketogenesis and sustained cell proliferation, all of which were connected to other KEs with non-adjacent KERs that were omitted from the analysis.

The number of shared AOPs by a KE varies between one and six AOPs. The interconnectivity between the AOPs in the network is fairly limited, as 78 % of the 82 KEs are included in merely one AOP (Figure 3a). Nevertheless, 22 % (*i.e.* absolute number: 18) KEs are shared by two or more AOPs. The directed eccentricity score showed that almost half (*i.e.* 45 %) of the KEs are categorised as downstream KEs, whilst 20 % should be regarded as upstream KEs. Accordingly, 35 % of the KEs cannot be categorised as either upstream or downstream due to their level of interconnectivity (Figure 3b).

The point at which the effects of separate stressors may converge to influence a common downstream KE can be the basis for predicting multiple stressors jointly, while measuring only one perturbation. *Vice versa*, divergent KEs indicate where AOPs are branching off from a common MIE or KE. Thus, identified points of convergence and divergence may indicate the most promising KEs for development of *in vitro* and/or *in silico* assays that can encapsulate all the pathways upstream from that particular KE (Knapen et al. 2018; Villeneuve et al. 2018). Because the KERs in an AOP network are directed, the degree of a node in the network (*i.e.* KE) can be broken down to indegree and outdegree, indicating KEs upstream and downstream, respectively, of any specific KE (Knapen et al. 2018; Villeneuve et al. 2018). By using the ratio between the indegree and outdegree, KEs can be attributed to be either convergent or divergent. In the derived hepatotoxicity AOP network,

accumulation of FA is the KE with the highest number of connections to upstream KEs with a value of 11, while being connected to six downstream KEs. This suggests that FA accumulation is a point of convergence, which demonstrates the importance of metabolism and transport in liver disease aetiology. As a matter of fact, FA accumulation is one of the KEs with the highest number of downstream relationships albeit being a point of convergence. Again, this makes sense, as steatosis is the defined AO in several AOPs in the network. Similarly, cell injury/death is a highly connected KE and point of convergence, with seven upstream and five downstream connections. The AO steatosis is regarded as a point of convergence as AOP ID 213/B-OXIDATION, leading to steatohepatitis, uses this AO as a KE. In contrast, activation of the liver X receptor (LXR), defined as a MIE, has one upstream and six downstream connections, of which all ultimately lead to steatosis, and therefore identified as a point of divergence. Mitochondrial dysfunction, shared by AOP ID 144/LYSOSOMAL UPTAKE, AOP ID 130/PHOSPHOLIPASE A and AOP ID 273/MITOCHONDRIAL INHIBITION, is a diverging KE triggered by four upstream events, including disruption of lysosomes, inhibition of phospholipase A, decreased oxidative phosphorylation and increased levels of mitochondrial ROS. Mitochondrial dysfunction leads to cell injury/death, vacuolisation of hepatocytes and Kupffer cells, ballooning of hepatocytes, increased levels of mitochondrial ROS and impaired proteostasis.

The eccentricity of a node in a directed graph measures the maximum distance from one node to any other node in the network. A lower eccentricity score implies a more downstream KE and *vice versa*. Conversely, in a non-directed analysis of a network, the eccentricity score depicts the distance from the centre of the network to that of a given node. Here, a low eccentricity score in an undirected graph therefore implies a more central KE, which in turn indicates what KEs are most easily influenced by other KEs with which they are interconnected. The calculation of eccentricity depends on path length, which is to some extent a subjective result of the number of KEs the AOP developer decides to include. This could vary depending on the AOP's level of maturity and detail. This means that the results can be misleading if the AOPs included in the network vary greatly in length (*i.e.* the numbers of KEs included in the network) (Villeneuve et al. 2018). The non-directed eccentricity score suggests that

cell injury/death, mitochondrial dysfunction, FA accumulation, bile accumulation, increased ROS, collagen accumulation, Mallory body formation, liver fibrosis and perturbation of cholesterol are the most centrally located KEs in the network with the score of seven (Figure S2, Appendix 2). The most upstream KEs, and therefore least sensitive to influence, are decreased oxidative phosphorylation and inhibition of N-linked glycosylation with a score of 12. Similarly, betweenness centrality measures the number of shortest paths between any KEs in the AOP network that passes through a particular KE, and thus could help to identify important KEs in the network. The KEs with the highest betweenness centrality scores were cell injury/death, steatosis, increased ROS, release of pro-inflammatory mediators, mitochondrial dysfunction and FA accumulation with scores of 3.71, 2.97, 2.96, 1.91, 1.78 and 1.59, respectively (Figure S3, Appendix 2).

The combined consideration of all parameters included in the topology analysis suggested that cell injury/death, increased ROS, mitochondrial dysfunction and FA accumulation are highly connected and central KEs in an AOP hepatotoxicity network. Table 3 provides an overview of available assays that can be used to measure endpoints, as well as a selection of representative stressors, associated with these four KEs.

All derived networks, including AOP networks, are sensitive to errors in the data underlying the network, which can affect the analysis and thus the conclusions drawn. A network with a high level of qualitative and quantitative evidence will contribute to the confidence in the selected *in vitro* and/or *in silico* assays used to predict hepatotoxicity. Therefore, the qualitative level of understanding of the relationship between pairs of KEs in the network was examined in the present study. The level of understanding, as reported by the AOP developers, is described as to be moderate or higher for 65 % of the KERs in the network. The qualitative level of understanding for 57 % of the KERs in the network is high (Figure 4). One AOP, AOP ID 130/PHOSPHOLIPASE A, which is still under development in the AOP-Wiki, stands out among the KERs described as low. Indeed, this particular AOP contributes to 20 out of the 22 KERs where the level of understanding is low. Moreover, the AOPs in the AOP-Wiki may

at a given time be at different stages of development, and thus some AOPs may be only partially complete. It has been demonstrated that the user-defined fields, such as title and description in the majority of the AOPs, KEs and KERs in the AOP-Wiki are only partially complete (Pollesch et al. 2019). AOPs, KEs and KERs only contained on average information in 49.2%, 47% and 26.3%, respectively, of the possible fields. The fields with the lowest amount of information were those associated with describing the supporting evidence. In the derived hepatotoxicity AOP network, AOP ID 209/SREBF2, AOP ID 273/MITOCHONDRIAL INHIBITION and AOP ID 285/GLYCOSYLATION, which are all under development in the AOP-Wiki, contain most cases (*i.e.* 23 out of 26) where the qualitative evidence is unspecified. Nevertheless, all AOPs, regardless of their stage of development, were included in the network characterisation and analysis.

## 4. Conclusions

Next generation non-animal safety assessment of chemicals is focused on hypothesis-driven approaches tailored to the characteristics and intended use of the chemical compound of interest. This paradigm shift in toxicology implies a need to move towards pathway-based strategies that are based on knowledge of the biological mechanisms underlying toxicity in potentially exposed organisms (Mahony et al. 2020). In this context, AOP networks, rather than individual linear AOPs, have emerged as tools for real-life applications, as they provide a more reliable reflection of the mechanistic complexity underlying chemical adversity (Edwards et al. 2016; Sakuratani et al. 2018; Sewell et al. 2018; Coady et al. 2019; Hecker and LaLone 2019). However, a detailed molecular understanding of all possible adversities may not be necessary, nor practical, in chemical safety assessment. Apart from highly specifically acting chemicals, the majority of chemical compounds are likely to perturb more than one AOP. AOP networks are therefore envisaged to be the functional units of prediction for most chemically induced AOs (Worth and Patlewicz, 2016). Hence, it appears logical to make use of KEs that are crucial and conserved across multiple AOPs related to the organ system of interest. In the current study, a previously introduced workflow to develop and analyse an AOP

network for neurotoxicity (Spinu et al. 2019) was applied to the case of hepatotoxicity. Although the derived AOP network almost certainly does not contain all underlying mechanisms of hepatotoxicity, this exercise provided guidance for the prioritisation of KEs for testing. A testing strategy derived from AOP networks includes *in vitro* and/or *in silico* assays that address the KEs capable of serving as alternatives to the measurement of apical AOs in animals. There is a large variety of mechanisms known to be involved in hepatotoxicity (Jaeschke et al. 2002; Russmann et al. 2009; Vinken et al. 2013b) which is reflected in the limited interconnectivity within the derived AOP network in the present study. Analytical characterisation of the AOP network based on individual AOPs currently available in the AOP-Wiki suggests that cell injury/death, increased ROS, mitochondrial dysfunction and FA accumulation are the most highly connected and central KEs. As such, these KEs may be considered for selecting, developing and optimising *in vitro* and/or *in silico* assays to predict hepatotoxicity induced by chemicals. It should be noted that *in vitro* assays must be selected carefully as overlap and redundancies between assays may exist. Nevertheless, there are AOPs that do not pass through any of these most common KEs. Thus, AOP ID 318/GR (GR activation leading to hepatic steatosis) is connected to the network solely through its AO steatosis. However, one may argue that FA accumulation always occurs *prior* the development of steatosis (Ipsen et al. 2018), even though FA accumulation is not present as a KE in AOP ID 318/GR. This may be attributed to the varying level of detail in the linear AOPs included in the network. Another AOP that does not pass through the identified KEs is AOP ID 285/GLYCOSYLATION (Inhibition of N-linked glycosylation leads to liver injury), which is connected to the AOP network through the KEs activation HSC and apoptosis. Again, this may be attributed to a varying level of detail in the KE descriptions. Despite the large efforts in the present study undertaken to harmonise KEs under common KE titles, the derived network contains four KEs that to some extent are related to cell death (cell injury/death, apoptosis, presence of necrotic tissue and increased oncotic necrosis). Although it is well known that cell death can manifest in different ways, this is not consistently reflected in the KEs descriptions. Specifically, the KE cell injury/death does not distinguish between apoptosis and necrosis, albeit the two elicit considerably different

cellular responses (Fink and Cookson, 2005). This greatly implicates KE harmonisation, and ultimately, AOP network derivation. Moreover, the KE annotations and descriptions impact the construction of an AOP network. When KEs and KERs are shared among multiple AOPs, the AOP-Wiki automatically generate connections between them. This allows information that has been used to build an AOP to be reused in subsequently developed AOPs, whilst revealing their interconnections. However, as seen in this exercise, there are many KEs titled differently, while having the same meaning and/or referring to the same event, thereby hampering this process. Moreover, attention should be paid to the nomenclature used for KE titles to ensure a sufficient level of detail. In this respect, 'FA accumulation' may oversimplify the more generalised process of disruption in FA metabolism and transport that can ultimately lead to compensatory changes in multiple mechanisms of the FA metabolism processes. Further harmonisation and review of the present and future contributions to the AOP-Wiki is warranted. In this regard, there is an opportunity to take advantage of efforts made in the field of ontology-based semantic mapping (Wang et al. 2019). It has been shown that semantic analysis may assist in developing future AOPs by selecting candidate events from the AOP-Wiki based on ontology-terms that are semantically similar to the MIE or AO of interest (Wang 2020), which could bypass the current challenge with differences in KE titles. Finally, the discussion on incomplete AOPs and KE descriptions should not be taken as critique of the specific AOP developers. It is merely intended to highlight areas in need of further improvement to facilitate advancement of the use of AOPs for risk assessment purposes.

It is important to recognise that the current 'AOP mining' approach is limited to the knowledge presently incorporated in the AOPs available in the AOP-Wiki. To illustrate, many nuclear hormone receptors, including pregnane X receptor (PXR) and constitutive androstane receptor (CAR), both included in the linear AOPs making up this AOP network, are known to have overlapping ligands whilst having a high degree of overlap in target genes related to the regulation of cholesterol homeostasis and energy metabolism (Krasowski et al. 2011). However, activation of CAR inhibits lipogenesis, whereas PXR activation promotes lipid accumulation (Mackowiak et al. 2018; Daujat-Chavanieu and

Gerbal-Chaloin 2020). Furthermore, as shown in Figure 1, one aspect that is missing in the derived AOP network is the well-established role of farnesoid X receptor (FXR) in the regulation of bile acid and lipid homeostasis (Stofan and Guo 2020). FXR is a ligand-activated transcription factor known to be involved in the control of bile acid synthesis and is critical in regulating the enterohepatic circulation of bile acids by inducing the expression of bile acid efflux transporters, such as the bile salt export pump (BSEP) and organic solute transporter (OST) $\alpha/\beta$ , and suppressing influx transporters (Stofan and Guo 2020; Sun et al. 2021). It has been shown that inhibition of BSEP alone may not be sufficient to induce cholestasis as also other efflux transporters (*i.e.* OST $\alpha/\beta$ ) play an important role in the compensatory mechanism (Jackson et al. 2016; Jackson et al. 2018). Actually, this has been published in regards to the AOP on cholestasis (AOP ID 27/BSEP) as part of an adaptive response to counteract the accumulation of bile acids (Gijbels et al. 2020). However, these mechanisms are not included in the AOP-Wiki. These nuclear receptor compensatory mechanisms and/or feedback loops are not well reflected in the present network. Despite the fact that AOPs are not intended to be chemical agnostic, such types of ligand- and/or target gene-overlap, as well as feedback-mechanisms, should be included when the application of AOPs shifts towards risk assessment, rather than solely hazard identification.

Qualitative AOPs inform on biological plausibility and can, for example, be used to guide the prioritisation of assays for inclusion in testing strategies and screening of chemicals. However, they typically do not determine the probability of the AO to occur under a specified exposure scenario and are thus not fit for quantitative risk assessment. Quantitative AOPs incorporate knowledge on the required level of perturbation needed to transition from one KE to the next, as well as informing on the modulating factors that can influence those relationships. Ultimately, a quantitative AOP should be precise enough to allow for a quantitative prediction of under what conditions, and to what degree, and AO is likely to occur for a given activation of a MIE (Villeneuve et al. 2014; Conolly et al. 2017; Wittwehr et al. 2017). In particular, quantitative AOPs may determine biological tipping points along a toxicity pathway (Spinu et al. 2020). In respect to the herein derived network, it is worth investigating



if the selected KEs become initiated simultaneously or as a step-wise process. Such discoveries could enable identification of common toxicity limiting steps for high priority focus in toxicology screening.

The AOP network proposed herein was evaluated in the context of any available AOP networks that study hepatotoxicity. At present, eleven AOP networks have been developed for several liver endpoints, including hepatic steatosis, hepatic fibrosis and hepatic cholestasis, as summarised in the supplementary material (Appendix 1). Their applications vary from development and WoE assessment (Vinken et al. 2013a; Angrish et al. 2016) to quantification of MIEs and/or KEs of an AOP network (Gadaleta et al. 2018; Perkins et al. 2019; Burgoon et al. 2020). In this respect, additional MIEs have been studied for their potency of inducing liver steatosis (Mellor et al. 2016) and a bioassay toolbox has been compiled for the *in vitro* assessment of KEs leading to liver steatosis (Luckert et al. 2018). However, none of the AOP networks has studied multiple outcomes. Hence, the AOP network developed herein offers the most advanced mechanistic representation given that it described linkages between several hepatic diseases and adverse effects, including liver cancer. In addition, the available AOP networks differ in terms of the level of details the construction contained, *e.g.* mechanistic knowledge, phenotype, genomics, proteomics, metabolomics. Thus, a combination of information was utilised to develop an AOP network for hepatic steatosis modelled as a Bayesian network (Burgoon et al. 2020). This underlines the challenge for harmonisation and integration of the diverse nature of information towards improved decision making in chemical risk assessment. The OECD AOP-Wiki represents an excellent repository in this sense, allowing for the curation, evaluation, and validation of linear AOPs and additionally safeguards the quality of the mechanistic data and facilitates the identification of knowledge gaps and prioritisation of testing strategies. Notably, solely two of the previously developed AOP networks (Appendix 1) included linear AOPs available in the OECD AOP-Wiki, as opposed to the AOP network *de novo* formulated. Two identified AOP networks were available in Cytoscape AOPXplorer (Burgoon 2021). This database is part of the AOP Knowledgebase and becomes essential for the development, analysis and storage of resultant AOP networks for real-world applications.

## Acknowledgements

The authors wish to thank Dr. Michelle Angrish of the U.S. Environmental Protection Agency who kindly provided information regarding AOP ID 62. The authors are grateful for the many insightful comments received by the, to the authors, anonymous reviewers, which helped to improve this manuscript.

## Declarations

### Funding

This work was financially supported by Cosmetics Europe as part of the Long Range Science Strategy (LRSS) programme, the European Chemical Industry Council (CEFIC), the Center for Alternatives to Animal Testing (CAAT) at Johns Hopkins University-USA, the Methusalem program of the Flemish government and the Scientific Fund Willy Gepts of the University Hospital of the VUB-Belgium. The funding agencies have not been involved in the study design, collection, analysis and interpretation of data, nor in the writing of the manuscript.

### Availability of data and material

All data analysed and generated during this study are included in this published article and its supplementary information files.

### Code availability

Cytoscape, version 3.8.0 (<https://cytoscape.org/>), RRID:SCR\_003032.

Microsoft® Office Excel Version 16.0.13906.35904, RRID:SCR\_016137

### Compliance with ethical standards

The manuscript does not contain clinical studies or patient data.

## References

- Alves-Bezerra M, Cohen DE (2018) Triglyceride metabolism in the liver. *Comprehensive Physiology* 8. <https://doi.org/10.1002/cphy.c170012>
- Angrish MM, Kaiser JP, McQueen CA, Chorley BN (2016) Tipping the balance: Hepatotoxicity and the 4 apical key events of hepatic steatosis. *Toxicological Sciences* 150:261–268. <https://doi.org/10.1093/toxsci/kfw018>
- Ankley GT, Bennett RS, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, Mount DR, Nichols JW, Russom CL, Schmieder PK, Serrano JA, Tietge JE, Villeneuve DL (2010) Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment. *Environmental Toxicology and Chemistry* 29:730–741. <https://doi.org/10.1002/etc.34>
- Burden N, Sewell F, Andersen ME, Boobis A, Chipman JK, Cronin MTD, Hutchinson TH, Kimber I, Whelan M (2015) Adverse Outcome Pathways can drive non-animal approaches for safety assessment. *Journal of Applied Toxicology* 35:971–975. <https://doi.org/10.1002/jat.3165>
- Burgoon LD (2021) AOPXplorer. In: Cytoscape App Store. <http://apps.cytoscape.org/apps/aopxplorer>. Accessed 1 Mar 2021
- Burgoon LD, Angrish M, Garcia-Reyero N, Pollesch N, Zupanic A, Perkins E (2020) Predicting the Probability that a Chemical Causes Steatosis Using Adverse Outcome Pathway Bayesian Networks (AOPBNs). *Risk Analysis* 40:512–523. <https://doi.org/10.1111/risa.13423>
- Carusi A, Davies MR, de Grandis G, Escher BI, Hodges G, Leung KMY, Whelan M, Willett C, Ankley GT (2018) Harvesting the promise of AOPs: An assessment and recommendations. *Science of the Total Environment* 628–629:1542–1556. <https://doi.org/10.1016/j.scitotenv.2018.02.015>
- Coady K, Browne P, Embry M, Hill T, Leinala E, Steeger T, Maślankiewicz L, Hutchinson T (2019) When Are Adverse Outcome Pathways and Associated Assays “Fit for Purpose” for Regulatory Decision-

- Making and Management of Chemicals? Integrated Environmental Assessment and Management 15:633–647. <https://doi.org/10.1002/ieam.4153>
- Conolly RB, Ankley GT, Cheng W, Mayo ML, Miller DH, Perkins EJ, Villeneuve DL, Watanabe KH (2017) Quantitative Adverse Outcome Pathways and Their Application to Predictive Toxicology. Environmental Science and Technology 51. <https://doi.org/10.1021/acs.est.6b06230>
- Daujat-Chavanieu M, Gerbal-Chaloin S (2020) Regulation of CAR and PXR Expression in Health and Disease. Cells 9
- Edwards SW, Tan YM, Villeneuve DL, Meek ME, McQueen CA (2016) Adverse Outcome Pathways-Organizing Toxicological Information to Improve Decision Making. The Journal of pharmacology and experimental therapeutics 356:170–181. <https://doi.org/10.1124/jpet.115.228239>
- Gadaleta D, Manganelli S, Roncaglioni A, Toma C, Benfenati E, Mombelli E (2018) QSAR Modeling of ToxCast Assays Relevant to the Molecular Initiating Events of AOPs Leading to Hepatic Steatosis. Journal of Chemical Information and Modeling 58:1501–1517. <https://doi.org/10.1021/acs.jcim.8b00297>
- Gijbels E, Vilas-Boas V, Annaert P, Vanhaecke T, Devisscher L, Vinken M (2020) Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Archives of Toxicology 94. <https://doi.org/10.1007/s00204-020-02691-9>
- Hartung T, FitzGerald RE, Jennings P, Mirams GR, Peitsch MC, Rostami-Hodjegan A, Shah I, Wilks MF, Sturla SJ (2017) Systems Toxicology: Real World Applications and Opportunities. Chemical Research in Toxicology 30:870–882. <https://doi.org/10.1021/acs.chemrestox.7b00003>
- Hecker M, LaLone CA (2019) Adverse Outcome Pathways: Moving from a Scientific Concept to an Internationally Accepted Framework. Environmental Toxicology and Chemistry 38:1152–1163. <https://doi.org/10.1002/etc.4385>

- Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P (2018) Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. *Cellular and Molecular Life Sciences* 75:3313–3327. <https://doi.org/10.1007/s00018-018-2860-6>
- Jackson JP, Freeman KM, Friley WW, St. Claire RL, Black C, Brouwer KR (2016) Basolateral Efflux Transporters: A Potentially Important Pathway for the Prevention of Cholestatic Hepatotoxicity. *Applied In Vitro Toxicology* 2. <https://doi.org/10.1089/aivt.2016.0023>
- Jackson JP, Freeman KM, St Claire RL, Black CB, Brouwer KR (2018) Cholestatic Drug Induced Liver Injury: A Function of Bile Salt Export Pump Inhibition and Farnesoid X Receptor Antagonism. *Applied In Vitro Toxicology* 4. <https://doi.org/10.1089/aivt.2018.0011>
- Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ (2002) Mechanisms of hepatotoxicity. *Toxicological Sciences* 65:166–176. <https://doi.org/10.1093/toxsci/65.2.166>
- Kleinstreuer NC, Sullivan K, Allen D, Edwards S, Mendrick DL, Embry M, Matheson J, Rowlands JC, Munn S, Maull E, Casey W (2016) Adverse outcome pathways: From research to regulation scientific workshop report. *Regulatory Toxicology and Pharmacology* 76:39–50. <https://doi.org/10.1016/j.yrtph.2016.01.007>
- Knapen D, Angrish MM, Fortin MC, Katsiadaki I, Leonard M, Margiotta-Casaluci L, Munn S, O’Brien JM, Pollesch N, Smith LC, Zhang X, Villeneuve DL (2018) Adverse outcome pathway networks I: Development and applications. *Environmental Toxicology and Chemistry* 37:1723–1733. <https://doi.org/10.1002/etc.4125>
- Krasowski MD, Ni A, Hagey LR, Ekins S (2011) Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. *Molecular and Cellular Endocrinology* 334
- Luckert C, Braeuning A, de Sousa G, Durinck S, Katsanou ES, Konstantinidou P, Machera K, Milani ES, Peijnenburg AACM, Rahmani R, Rajkovic A, Rijkers D, Spyropoulou A, Stamou M, Stoop G, Sturla S, Wollscheid B, Zucchini-Pascal N, Lampen A (2018) Adverse Outcome Pathway-Driven

- Analysis of Liver Steatosis in Vitro: A Case Study with Cyproconazole. *Chemical Research in Toxicology* 31:784–798. <https://doi.org/10.1021/acs.chemrestox.8b00112>
- Mackowiak B, Hodge J, Stern S, Wang H (2018) The roles of xenobiotic receptors: Beyond chemical disposition. *Drug Metabolism and Disposition* 46
- Mahony C, Ashton RS, Birk B, Boobis AR, Cull T, Daston GP, Ewart L, Knudsen TB, Manou I, Maurer-Stroh S, Margiotta-Casaluci L, Müller BP, Nordlund P, Roberts RA, Steger-Hartmann T, Vandenbossche E, Viant MR, Vinken M, Whelan M, Zvonimir Z, Cronin MTD (2020) New ideas for non-animal approaches to predict repeated-dose systemic toxicity: Report from an EPAA Blue Sky Workshop. *Regulatory Toxicology and Pharmacology* 114:104668. <https://doi.org/10.1016/j.yrtph.2020.104668>
- Mellor CL, Steinmetz FP, Cronin MTD (2016) The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways. *Critical Reviews in Toxicology* 46:138–152. <https://doi.org/10.3109/10408444.2015.1089471>
- OECD (2017) Guidance document on developing and assessing Adverse Outcome Pathways. Series on Testing and Assessment, OECD Publications. OECD Environment, Health and Safety Publications Series on Testing and Assessment 184
- OECD (2018) Users Handbook supplement to the Guidance Document for developing and assessing Adverse Outcome Pathways, OECD Series on Adverse Outcome Pathways, No. 1, OECD Publishing, Paris. Organisation for Economic Co-operation and Development publishing
- Parish ST, Aschner M, Casey W, Corvaro M, Embry MR, Fitzpatrick S, Kidd D, Kleinstreuer NC, Lima BS, Settivari RS, Wolf DC, Yamazaki D, Boobis A (2020) An evaluation framework for new approach methodologies (NAMs) for human health safety assessment. *Regulatory Toxicology and Pharmacology* 112. <https://doi.org/10.1016/j.yrtph.2020.104592>

- Perkins EJ, Ashauer R, Burgoon L, Conolly R, Landesmann B, Mackay C, Murphy CA, Pollesch N, Wheeler JR, Zupanec A, Scholz S (2019) Building and Applying Quantitative Adverse Outcome Pathway Models for Chemical Hazard and Risk Assessment. *Environmental Toxicology and Chemistry* 38:1850–1865
- Pollesch NL, Villeneuve DL, O'Brien JM (2019) Extracting and Benchmarking Emerging Adverse Outcome Pathway Knowledge. *Toxicological Sciences* 168:349–364. <https://doi.org/10.1093/toxsci/kfz006>
- Russmann S, Kullak-Ublick G, Grattagliano I (2009) Current Concepts of Mechanisms in Drug-Induced Hepatotoxicity. *Current Medicinal Chemistry* 16:3041–3053. <https://doi.org/10.2174/092986709788803097>
- Sakuratani Y, Horie M, Leinala E (2018) Integrated Approaches to Testing and Assessment: OECD Activities on the Development and Use of Adverse Outcome Pathways and Case Studies. *Basic and Clinical Pharmacology and Toxicology* 123:20–28. <https://doi.org/10.1111/bcpt.12955>
- Sewell F, Gellatly N, Beaumont M, Burden N, Currie R, de Haan L, Hutchinson TH, Jacobs M, Mahony C, Malcomber I, Mehta J, Whale G, Kimber I (2018) The future trajectory of adverse outcome pathways: a commentary. *Archives of Toxicology* 92:1657–1661. <https://doi.org/10.1007/s00204-018-2183-2>
- Spinu N, Bal-Price A, Cronin MTD, Enoch SJ, Madden JC, Worth AP (2019) Development and analysis of an adverse outcome pathway network for human neurotoxicity. *Archives of Toxicology* 93:2759–2772. <https://doi.org/10.1007/s00204-019-02551-1>
- Spinu N, Cronin MTD, Enoch SJ, Madden JC, Worth AP (2020) Quantitative adverse outcome pathway (qAOP) models for toxicity prediction. *Archives of Toxicology* 94
- Stofan M, Guo GL (2020) Bile Acids and FXR: Novel Targets for Liver Diseases. *Frontiers in Medicine* 7

- Sturla SJ, Boobis AR, Fitzgerald RE, Hoeng J, Kavlock RJ, Schirmer K, Whelan M, Wilks MF, Peitsch MC (2014) Systems toxicology: From basic research to risk assessment. *Chemical Research in Toxicology* 27:314–329. <https://doi.org/10.1021/tx400410s>
- Sun L, Cai J, Gonzalez FJ (2021) The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. *Nature Reviews Gastroenterology and Hepatology* 18
- Villeneuve DL, Angrish MM, Fortin MC, Katsiadaki I, Leonard M, Margiotta-Casaluci L, Munn S, O'Brien JM, Pollesch NL, Smith LC, Zhang X, Knapen D (2018) Adverse outcome pathway networks II: Network analytics. *Environmental Toxicology and Chemistry* 37:1734–1748. <https://doi.org/10.1002/etc.4124>
- Villeneuve DL, Crump D, Garcia-Reyero N, Hecker M, Hutchinson TH, LaLone CA, Landesmann B, Lettieri T, Munn S, Nepelska M, Ottinger MA, Vergauwen L, Whelan M (2014) Adverse outcome pathway (AOP) development I: Strategies and principles. *Toxicological Sciences* 142:312–320. <https://doi.org/10.1093/toxsci/kfu199>
- Vinken M (2013) The adverse outcome pathway concept: A pragmatic tool in toxicology. *Toxicology* 312:158–165. <https://doi.org/10.1016/j.tox.2013.08.011>
- Vinken M (2018) Taking adverse outcome pathways to the next level. *Toxicology in Vitro* 50:A1–A2. <https://doi.org/10.1016/j.tiv.2018.03.017>
- Vinken M, Knapen D, Vergauwen L, Hengstler JG, Angrish M, Whelan M (2017) Adverse outcome pathways: a concise introduction for toxicologists. *Archives of Toxicology* 91:3697–3707. <https://doi.org/10.1007/s00204-017-2020-z>
- Vinken M, Landesmann B, Goumenou M, Vinken S, Shah I, Jaeschke H, Willett C, Whelan M, Rogiers V (2013a) Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury. *Toxicological Sciences* 136:97–106. <https://doi.org/10.1093/toxsci/kft177>



- Vinken M, Maes M, Vanhaecke T, Rogiers V (2013b) Drug-Induced Liver Injury: Mechanisms, Types and Biomarkers. *Current Medicinal Chemistry* 20:3011–3021. <https://doi.org/10.2174/0929867311320240006>
- Wang RL (2020) Semantic characterization of adverse outcome pathways. *Aquatic Toxicology* 222. <https://doi.org/10.1016/j.aquatox.2020.105478>
- Wang RL, Edwards S, Ives C (2019) Ontology-based semantic mapping of chemical toxicities. *Toxicology* 412. <https://doi.org/10.1016/j.tox.2018.11.005>
- Wittwehr C, Aladjov H, Ankley G, Byrne HJ, de Knecht J, Heinzle E, Klambauer G, Landesmann B, Luijten M, MacKay C, Maxwell G, Meek MEB, Paini A, Perkins E, Sobanski T, Villeneuve D, Waters KM, Whelan M (2017) How adverse outcome pathways can aid the development and use of computational prediction models for regulatory toxicology. *Toxicological Sciences* 155. <https://doi.org/10.1093/toxsci/kfw207>
- Worth AP, Patlewicz G (2016) Integrated Approaches to Testing and Assessment. In: Eskes Chantra and Whelan M (ed) *Validation of Alternative Methods for Toxicity Testing*. Springer International Publishing, Cham, pp 317–342

**Table 1**

| ID  | TITLE   | MOLECULAR EVENT                       | INITIATING                         | ADVERSE OUTCOME | AUTHOR STATUS   | OECD STATUS         | AVAILABLE VIA   |
|-----|---|---------------------------------------|------------------------------------|-----------------|---|---------------------|---|
| 27  | Cholestatic liver injury induced by inhibition of the bile salt export pump (ABCB11)  | Inhibition, Bile salt export pump     |                                    | Cholestasis     | Under development: Not open for comment. Do not cite  | Under Development   | <a href="https://aopwiki.org/aops/27">https://aopwiki.org/aops/27</a>   |
| 36  | Peroxisomal fatty acid beta-oxidation inhibition leading to steatosis   | Decreased activation                  | PPAR $\alpha$ / $\beta$ / $\gamma$ | Steatosis       | Under Development: Contributions and Comments Welcome | -                   | <a href="https://aopwiki.org/aops/36">https://aopwiki.org/aops/36</a>   |
| 38  | Protein alkylation leading to liver fibrosis  | Alkylation, Protein                   |                                    | Fibrosis        | Open for citation & comment                           | TFHA/WNT Endorsed   | <a href="https://aopwiki.org/aops/38">https://aopwiki.org/aops/38</a>   |
| 58  | NR1I3 (CAR) suppression leading to hepatic steatosis  | Suppression, (multiple)               | CAR                                | Steatosis       | Under Development: Contributions and Comments Welcome | -                   | <a href="https://aopwiki.org/aops/58">https://aopwiki.org/aops/58</a>   |
| 60  | NR1I2 (pregnane X receptor, PXR) activation leading to hepatic steatosis  | Activation, PXR                       |                                    | Steatosis       | Under Development: Contributions and Comments Welcome | -                   | <a href="https://aopwiki.org/aops/60">https://aopwiki.org/aops/60</a>   |
| 130 | Phospholipase A inhibitors lead to hepatotoxicity   | Inhibition, Phospholipase A           |                                    | Fibrosis        | Under Development: Contributions and Comments Welcome | Under Development   | <a href="https://aopwiki.org/aops/130">https://aopwiki.org/aops/130</a> |
| 144 | Endocytic lysosomal uptake leading to liver fibrosis  | Endocytic uptake                      | lysosomal                          | Fibrosis        | Under development: Not open for comment. Do not cite  | EAGMST Under Review | <a href="https://aopwiki.org/aops/144">https://aopwiki.org/aops/144</a> |
| 209 | Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP | No MIE defined (Upregulation, SREBF2) |                                    | Hepatotoxicity  | Under development: Not open for comment. Do not cite  | -                   | <a href="https://aopwiki.org/aops/209">https://aopwiki.org/aops/209</a> |
| 213 | Inhibition of fatty acid beta oxidation leading to non-alcoholic steatohepatitis (NASH)   | Decreased, $\beta$ -oxidation         |                                    | Steatohepatitis | Open for adoption                                     | -                   | <a href="https://aopwiki.org/aops/213">https://aopwiki.org/aops/213</a> |
| 220 | CYP2E1 activation leading to liver cancer   | Activation, CYP2E1                    |                                    | Cancer          | Open for citation & comment                           | EAGMST Under Review | <a href="https://aopwiki.org/aops/220">https://aopwiki.org/aops/220</a> |
| 273 | Mitochondrial complex inhibition leading to liver injury  | Mitochondrial inhibition (multiple)   |                                    | Liver injury    | Under development: Not open for comment. Do not cite  | -                   | <a href="https://aopwiki.org/aops/273">https://aopwiki.org/aops/273</a> |
| 278 | IKK complex inhibition leading to liver injury  | Inhibition, IKK complex               |                                    | Liver injury    | Under development: Not open for comment. Do not cite  | -                   | <a href="https://aopwiki.org/aops/278">https://aopwiki.org/aops/278</a> |
| 285 | Inhibition of N-linked glycosylation leads to liver injury  | Inhibition, glycosylation             | N-linked                           | Liver injury    | Under development: Not open for comment. Do not cite  | -                   | <a href="https://aopwiki.org/aops/285">https://aopwiki.org/aops/285</a> |
| 318 | Glucocorticoid receptor activation leading to hepatic steatosis   | Activation, GR (multiple)             |                                    | Steatosis       | Under Development: Contributions and Comments Welcome | -                   | <a href="https://aopwiki.org/aops/318">https://aopwiki.org/aops/318</a> |

**Table 1** Linear AOPs for hepatotoxicity included in the AOP network. CAR Constitutive Androstane Receptor; CYP2E1 Cytochrome P450 2E1; GR Glucocorticoid Receptor; MIE Molecular initiating event; OECD Organisation for Economic Co-operation and Development.

#### Convergent KEs

| <i>KE type</i> | <i>KE name</i>                       |
|----------------|--------------------------------------|
| KE             | Accumulation, FA                     |
| KE             | Activation, SREBF1                   |
| KE             | Ballooning (hepatocyte)              |
| AO             | Cell injury/death                    |
| AO             | Cholestasis, Pathology               |
| KE             | Decreased, HSD17B10 expression       |
| KE             | Decreased, Ketogenesis               |
| KE             | Decreased, Oxidative phosphorylation |
| KE             | Formation, Mallory body              |
| KE             | Increased, De novo FA synthesis      |
| KE             | Increased, TG formation              |
| AO             | Liver fibrosis                       |
| AO             | Liver injury                         |
| KE             | Perturbation of cholesterol          |
| AO             | Steatohepatitis                      |
| AO             | Steatosis                            |
| KE             | Sustained cell proliferation         |
| KE             | Up Regulation, ACC-1                 |
| KE             | Up Regulation, SCD-1                 |
| KE             | Vacuolization (bile duct cell)       |
| KE             | Vacuolization (hepatocyte)           |
| KE             | Vacuolization (kupffer cell)         |

#### Divergent KEs

| <i>KE type</i> | <i>KE name</i>   |
|----------------|--|
| MIE            | Activation, CYP2E1   |
| MIE            | Activation, GR   |
| MIE            | Activation, LXR  |
| MIE            | Activation, PXR  |
| KE             | Apoptosis  |
| KE             | Bile accumulation  |
| MIE            | Binding of inhibitor, mitochondrial complex III                  |
| MIE            | Binding of inhibitor, mitochondrial complex IV                   |
| MIE            | Binding of inhibitor, mitochondrial complex V                    |
| MIE            | Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) |
| KE             | Damage, Lipid bilayer  |
| MIE            | Decreased, PPAR- $\alpha$ activation                             |
| MIE            | Decreased, PPAR- $\beta$ activation                              |
| MIE            | Decreased, PPAR- $\gamma$ activation                             |
| KE             | Decreased, $\beta$ -oxidation                                    |
| MIE            | Demethylation, PPAR- $\gamma$ promoter                           |
| KE             | Disturbance, Lysosomal function                                  |
| KE             | Down Regulation, GSS and GSTs gene                               |
| MIE            | Endocytotic lysosomal uptake                                     |
| MIE            | Inhibition of N-linked glycosylation                             |
| MIE            | Inhibition, BSEP   |
| KE             | Inhibition, FoxA2  |
| MIE            | Inhibition, IKK complex  |
| MIE            | Inhibition, Phospholipase A                                      |
| KE             | Mitochondrial dysfunction  |
| MIE            | Protein Alkylation   |
| MIE            | Suppression, CAR   |
| KE             | Up Regulation, SREBF2  |

**Table 2** The analysis of the in-degree and out-degree confirmed 22 convergent KEs and 28 divergent KEs.


Table 3

| Key event                 | Representative stressors  | Endpoint measured                  | Methodology  | References   |
|---------------------------|---|------------------------------------|--|--|
| Cell injury/ death        | Isoniazid, paracetamol, phenobarbital, propranolol, verapamil*    | Oxidoreductase enzyme activity     | Detection of formazan product derived from reduction in viable cells of tetrazolium substrates MTT, MTS, XTT.                                | Riss et al. (2016)   |
|                           |   | Lactate dehydrogenase leakage      | Bioluminescent representation of LDH activity in extracellular medium, indicating its effluence from damaged cells.                          | Chan et al. (2013)   |
|                           |   | Neutral red uptake                 | Quantification of the internalisation of fluorescent neutral red dye, occurring exclusively within viable cells.                             | Repetto et al. (2008)  |
|                           |   | Protease enzyme activity           | Assaying of protease enzyme activity, through cleavage of peptide (GF-AFC) in functional cells.  | Riss et al. (2016)   |
| Oxidative stress          | Chloroform, 1,2-dichlorobenzene, furan, menadione, valproic acid  | ROS presence                       | Quantification of fluorescence of dihydroethidium or fluorescein derivatives.  | Kalyanaraman et al. (2012)   |
|                           |   | Oxidation of DNA                   | Detection of 8-hydroxydeoxyguanosine formation (as ELISA).   | Dasgupta and Klein (2014)  |
|                           |   | Peroxidation of lipids             | Detection of malondialdehyde presence, through reactivity with TBARS.  | Dasgupta and Klein (2014)  |
|                           |   | Protein oxidation                  | Identification of markers of oxidative damage, such as protein carbonylation and advanced glycation end products.                            | Dasgupta and Klein (2014)  |
| Mitochondrial dysfunction | 2,4-dinitrophenol, HCN, pentachlorophenol rotenone, zidovudine    | Respirometry                       | Monitoring response in oxygen consumption in order to infer efficiency of OXPHOS, either through polarimetry or extracellular flux analysis. | Horan et al. (2012)  |
|                           |   | Membrane potential depletion       | Assaying of fluorescent rhodamine dye uptake into polarised mitochondria.  | Perry et al. (2011)  |
|                           |   | ATP production                     | Luciferase-based bioluminescent determination of ATP concentration (also used as proxy for general cell viability).                          | Riss et al. (2016)   |
|                           |   | Reduction in glycolysis dependence | Promotion of OXPHOS reliance in cancer cell lines, enabling mitochondrial liability to be emphasised.  | Marroquin et al. (2007)  |
| Fatty acid accumulation   | Amiodarone, fenofibrate, tetracycline, ticlodipine, valproic acid | Intracellular lipid content        | Quantification of BODIPY, Nile red or Oil Red O fluorescence in treated, cultured cells (HepG2, HepaRG).                                     | Muller and Sturla (2019), Donato et al. (2012), Gomez-Lechon et al. (2007), Tolosa et al. (2016) |

**Table 3** Overview of assays that can be used to measure endpoints associated with the four KEs (cell injury/death, increased ROS, mitochondrial dysfunction and FA accumulation) identified as the most highly connected and central KEs in an AOP hepatotoxicity network. Abbreviations: ELISA Enzyme-linked immunosorbent assay; GF-AFC Glycylphenylalanyl-aminofluorocoumarin; MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MTT 3,-4,5 dimethylthiazol-2,5 diphenyl tetrazolium bromide; ROS Reactive oxygen species; OXPPOS Oxidative phosphorylation; TBARS Thiobarbituric acid reactive substance assay; XTT 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide.




## Figures



**Figure 1** The network consisting of 14 AOPs available in the AOP-Wiki related to hepatotoxicity (extracted 1 September 2020) that share at least one KE. MIEs, KEs and AOs are coloured yellow, blue and red, respectively. Solid arrows indicate adjacent KER, with the arrow emanating from the upstream KE and into the downstream KE. KERs shared by more than one AOP are represented by a single arrow. KER label indicates strength of evidence as defined by the AOP author in the AOP-Wiki where H=high, M=medium, L=low. No label indicates lack of information in the AOP-Wiki. Curated KE titles, including abbreviations, are available as supplementary information (Appendix 1). KE Key event; KER Key event relationship; MIE molecular initiating event; AO Adverse outcome.




a




b

| KE Title                            | Included in AOPs (AOP ID)  |
|-------------------------------------|--|
| Cell injury/death                   | 36/PPAR; 144/LYSOSOMAL UPTAKE; 209/SREBF2; 220/CYP2E1; 273/MITOCHONDRIAL INHIBITION; 278/IKK |
| Accumulation, FA                    | 36/PPAR; 58/CAR; 60/PXR; 130/PHOSPHOLIPASE A; 213/B-OXIDATION                                |
| Decreased, β-oxidation              | 36/PPAR; 58/CAR; 60/PXR; 213/B-OXIDATION; 318/GR   |
| Steatosis                           | 36/PPAR; 58/CAR; 60/PXR; 213/B-OXIDATION; 318/GR   |
| Activation, HSC                     | 38/PROTEIN ALKYLATION; 144/LYSOSOMAL UPTAKE; 285/GLYCOSYLATION                               |
| Decreased, PPAR-α activation        | 36/PPAR; 58/CAR; 318/GR  |
| Increased, ROS                      | 27/BSEP; 213/B-OXIDATION; 220/CYP2E1   |
| Liver fibrosis                      | 38/PROTEIN ALKYLATION; 130/PHOSPHOLIPASE A; 144/LYSOSOMAL UPTAKE                             |
| Liver injury                        | 273/MITOCHONDRIAL INHIBITION; 278/IKK; 285/GLYCOSYLATION                                     |
| Mitochondrial dysfunction           | 130/PHOSPHOLIPASE A; 144/LYSOSOMAL UPTAKE; 273/MITOCHONDRIAL INHIBITION;                     |
| Release, Pro-inflammatory mediators | 27/BSEP; 38/PROTEIN ALKYLATION; 144/LYSOSOMAL UPTAKE   |
| Accumulation, Collagen              | 38/PROTEIN ALKYLATION; 144/LYSOSOMAL UPTAKE  |
| Increased, De novo FA synthesis     | 58/CAR; 209/SREBF2   |
| Increased, FA influx                | 58/CAR; 60/PXR   |
| Increased, TG formation             | 58/CAR; 60/PXR   |
| Necrotic tissue                     | 273/MITOCHONDRIAL INHIBITION; 278/IKK  |
| Up Regulation, CD36                 | 58/CAR; 60/PXR   |
| Up Regulation, SCD-1                | 58/CAR; 60/PXR   |

**Figure 2** (a) KEs shared by more than one AOP. The score indicates the number of AOPs in which the KE is present. Cell injury/death is included in the highest number of AOPs, followed by FA accumulation, decreased,  $\beta$ -oxidation and steatosis. (b) The distribution of the shared KEs among the linear AOPs included in the network. AOP Adverse outcome pathway; CD36 Cluster of differentiation 36; FA Fatty acid; HSC Hepatic stellate cell; KE Key event; SCD-1 Stearoyl-CoA desaturase-1; ROS Reactive oxygen species; TG Triglyceride.



**Figure 3** (a) The distribution of KEs in shared AOPs show that the interconnectivity between the AOPs in the network is fairly limited. (b) The distribution of KEs according to the directed eccentricity score shows that 35 % of the KEs cannot be categorised as either upstream or downstream due to their level of interconnectivity (*i.e.* eccentricity score between 3-6).



**Figure 4** The distribution of the weight of evidence for KERs as reported by the AOP developers.

## Supplementary material

### Appendix 1

This Excel file contains all collected material used to derive the network, including KE annotation changes described in section 2.2. of the Materials and Methods, as well as NetworkAnalyzer output.

### Appendix 2

This Word file contains supplementary figures describing the topological analysis of the derived AOP network for hepatotoxicity.